Cargando…

Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review

Repository corticotropin injection (RCI; Acthar(®) Gel) is approved by the US Food and Drug Administration (FDA) for use in 19 indications, including for the treatment of selected patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), symptomatic sarcoidosis, uveitis, and kerat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Girman, Cynthia, Panaccio, Mary P., Hayes, Kyle, Niewoehner, John, Wan, George J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239937/ https://www.ncbi.nlm.nih.gov/pubmed/35635646 http://dx.doi.org/10.1007/s12325-022-02176-4

Ejemplares similares

Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis
por: Bindra, Jas, et al.
Publicado: (2022)

Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis
por: Bindra, Jas, et al.
Publicado: (2021)

Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis
por: Hunter, Samuel F, et al.
Publicado: (2021)

Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis
por: Busch, Howard, et al.
Publicado: (2022)

Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection
por: Hayes, Kyle, et al.
Publicado: (2021)

Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis
por: Hayes, Kyle, et al.
Publicado: (2021)

Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis
por: Rice, J. Bradford, et al.
Publicado: (2020)

Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2022)

Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications
por: Philbin, Michael, et al.
Publicado: (2017)

Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2021)

Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review
por: Mirsaeidi, Mehdi, et al.
Publicado: (2022)

Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis
por: Wan, George J, et al.
Publicado: (2020)

A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2022)

Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab
por: Knight, Tyler, et al.
Publicado: (2017)

A Systematic Literature Review and Indirect Treatment Comparison of Efficacy of Repository Corticotropin Injection versus Synthetic Adrenocorticotropic Hormone for Infantile Spasms
por: Duchowny, Michael S., et al.
Publicado: (2021)

Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies
por: Patel, Aarat, et al.
Publicado: (2016)

Treatment of fibrillary glomerulonephritis with use of repository corticotropin injections
por: Maroz, Natallia, et al.
Publicado: (2018)

Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model
por: Hayes, Kyle, et al.
Publicado: (2020)

Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar(®) Gel) for Persistently Active Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2021)

Repository corticotropin injection attenuates collagen-induced arthritic joint structural damage and has enhanced effects in combination with etanercept
por: Decker, Dima A., et al.
Publicado: (2020)

Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies
por: Fischer, Peter A, et al.
Publicado: (2018)

Treatment of Noninfectious Retinal Vasculitis Using Subcutaneous Repository Corticotropin Injection
por: Anesi, Stephen D., et al.
Publicado: (2021)

Correction to: Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model
por: Hayes, Kyle, et al.
Publicado: (2020)

Repository corticotropin for Chronic Pulmonary Sarcoidosis
por: Baughman, Robert P., et al.
Publicado: (2017)

Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records
por: Chopra, Ishveen, et al.
Publicado: (2019)

Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series
por: Brown, Alan N
Publicado: (2016)

Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone
por: Lal, Ritu, et al.
Publicado: (2015)

Repository Corticotropin Injections Promote Clinical Remission and Regulatory T Cell Expansion in Membranous Nephropathy
por: Hartzell, Susan, et al.
Publicado: (2021)

Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus
por: Bindra, Jas, et al.
Publicado: (2022)

Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis
por: Bindra, Jas, et al.
Publicado: (2023)

H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes
por: Kutz, Christen
Publicado: (2016)

Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis
por: Ho-Mahler, Nancy, et al.
Publicado: (2020)

A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse
por: Kaplan, Jeffrey, et al.
Publicado: (2020)

Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin
por: Hartung, Daniel M., et al.
Publicado: (2018)

Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence
por: Wan, George J, et al.
Publicado: (2023)

Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States
por: Nelson, Winnie W., et al.
Publicado: (2019)

Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms
por: Gold, Laura S, et al.
Publicado: (2019)

Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
por: Fleischmann, Roy, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH(1‐24) Depot and Methylprednisolone in Healthy Subjects
por: Poola, Nagaraju, et al.
Publicado: (2021)

A Randomized Prospective Trial Comparing Repository Corticotropin Injection and Intravenous Methylprednisolone for Neuroprotection in Acute Optic Neuritis
por: Bennett, Jeffrey L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v09fcb6co4i2pk72o9f3q28q7s